
HEM Pharmaco Targets 2026 Profit With US Launch of Gut Microbiome Platform
HEM Pharmaco aims to turn a profit next year by launching its AI gut microbiome platform Vignal in the US market....
Korean business news covering major corporations, industrial sectors, semiconductors, and trade.

HEM Pharmaco aims to turn a profit next year by launching its AI gut microbiome platform Vignal in the US market....








![Corporate Disclosures [August 25] - Seoul Economic Daily South Korea Business & Industry News from South Korea](https://wimg.sedaily.com/news/cms/2026/08/25/20083133?ref=sedailyEng_1.jpg)